21 Hits in 1.7 sec

Communications for AnyPLACE: A smart metering platform with management and control functionalities

Dominik Henneke, Christian Freudenmann, Markus Kammerstetter, David Rua, Lukasz Wisniewski, Jurgen Jasperneite
2016 2016 IEEE 21st International Conference on Emerging Technologies and Factory Automation (ETFA)  
Recent developments under the term Smart Grid change how users consume electricity and interact with the power grid. Smart metering and energy management are developments that transform the yet passive energy consumer to a participant that is actively involved in the energy market by using variable energy tariffs or by demand-response services. But such functionality demands a platform that integrates all smart devices in the users property, connects to external services and electricity
more » ... s, and has interfaces that provide information and control to the user. AnyPLACE will develop such platform. Based on the latest legislation in the European member states, it will incorporate smart meters and create links to external service providers. Furthermore, it connects the devices in the property of the end-user in order to be able to fully monitor and control the energy consumption. This paper presents the AnyPLACE idea and the problems that are solved on the communications aspect. It provides an in-depth analysis of current European legislation in the context of smart metering and provides the requirements that need to be realized by the platform. Additionally, it proposes a strategy to create a solution that can be used in any place of Europe. The paper also incorporates the security and privacy requirements in different domains and sketches a solution and architecture to fulfill these by incorporating existing open source implementations as provided by the openHAB project.
doi:10.1109/etfa.2016.7733496 dblp:conf/etfa/HennekeFKRWJ16 fatcat:6tazdsyt6rbljelf5sv3xbxlre

Preclinical efficacy of a PSMA-targeted thorium-227 conjugate (PSMA-TTC), a targeted alpha therapy for prostate cancer

Stefanie Hammer, Urs B Hagemann, Sabine Zitzmann-Kolbe, Aasmund Larsen, Christine Ellingsen, Solene Geraudie, Derek Grant, Baard Indrevoll, Roger Smeets, Oliver von Ahsen, Alexander Kristian, Pascale Lejeune (+6 others)
2019 Clinical Cancer Research  
Hennekes is an employee of and holds ownership interest in Bayer AG. J. Karlsson, R.M. Bjerke, and O.B. Ryan are employees/paid consultants for Bayer AS. A.S.  ... 
doi:10.1158/1078-0432.ccr-19-2268 pmid:31831560 fatcat:ovi526r5vrhm7ddhwvx4qf4lmi

Darolutamide potentiates the antitumor efficacy of a PSMA-targeted thorium-227 conjugate (PSMA-TTC) by a dual mode-of-action in prostate cancer models

Stefanie Hammer, Andreas Schlicker, Sabine Zitzmann-Kolbe, Simon Baumgart, Urs B. Hagemann, Arne Scholz, Bernard Haendler, Pascale Lejeune, Jenny Karlsson, Christine Ellingsen, Hartwig Hennekes, Carsten H. Nielsen (+3 others)
2021 Clinical Cancer Research  
Androgen receptor (AR) inhibitors are well-established in the treatment of castration-resistant prostate cancer (CRPC) and have recently shown efficacy also in castration-sensitive prostate cancer (CSPC). Although most patients respond well to initial therapy, resistance eventually develops, and thus, more effective therapeutic approaches are needed. Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer and presents an attractive target for radionuclide therapy. Here,
more » ... we evaluated the efficacy and explored the mode-of-action of the PSMA-targeted thorium-227 conjugate (PSMA-TTC) BAY 2315497, an antibody-based targeted alpha therapy, in combination with the AR inhibitor darolutamide. The in vitro and in vivo antitumor efficacy and mode-of-action of the combination treatment were investigated in preclinical cell line- and patient-derived prostate cancer xenograft models with different levels of PSMA expression. Darolutamide induced the expression of PSMA in androgen-sensitive VCaP and LNCaP cells in vitro, and the efficacy of darolutamide in combination with PSMA-TTC was synergistic in these cells. In vivo, the combination treatment showed synergistic antitumor efficacy in the low PSMA-expressing VCaP and in the high PSMA-expressing ST1273 prostate cancer models, and enhanced efficacy in the enzalutamide-resistant KUCaP-1 model. The treatments were well-tolerated. Mode-of-action studies revealed that darolutamide induced PSMA expression, resulting in higher tumor uptake of PSMA-TTC, and consequently, higher antitumor efficacy, and impaired PSMA-TTC-mediated induction of DNA damage repair genes, potentially contributing to increased DNA damage. Conclusions/Discussion: These results provide a strong rationale to investigate PSMA-TTC in combination with AR inhibitors in patients with prostate cancer.
doi:10.1158/1078-0432.ccr-21-0342 pmid:34035067 fatcat:mod7mdyjurgprfamioq4wixuvu

Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy

Pascale Lejeune, Véronique Cruciani, Axel Berg-Larsen, Andreas Schlicker, Anne Mobergslien, Lisa Bartnitzky, Sandra Berndt, Sabine Zitzmann-Kolbe, Claudia Kamfenkel, Stefan Stargard, Stefanie Hammer, Jennifer S Jørgensen (+8 others)
2021 Journal for ImmunoTherapy of Cancer  
Targeted thorium-227 conjugates (TTCs) are an emerging class of targeted alpha therapies (TATs). Their unique mode of action (MoA) is the induction of difficult-to-repair clustered DNA double-strand breaks. However, thus far, their effects on the immune system are largely unknown. Here, we investigated the immunostimulatory effects of the mesothelin-targeted thorium-227 conjugate (MSLN-TTC) in vitro and in vivo in monotherapy and in combination with an inhibitor of the immune checkpoint
more » ... ed death receptor ligand 1 (PD-L1) in immunocompetent mice. The murine cell line MC38 was transfected with the human gene encoding for MSLN (hMSLN) to enable binding of the non-cross-reactive MSLN-TTC. The immunostimulatory effects of MSLN-TTC were studied in vitro on human cancer cell lines and MC38-hMSLN cells. The efficacy and MoA of MSLN-TTC were studied in vivo as monotherapy or in combination with anti-PD-L1 in MC38-hMSLN tumor-bearing immunocompetent C57BL/6 mice. Experiments were supported by RNA sequencing, flow cytometry, immunohistochemistry, mesoscale, and TaqMan PCR analyses to study the underlying immunostimulatory effects. In vivo depletion of CD8+ T cells and studies with Rag2/Il2Rg double knockout C57BL/6 mice were conducted to investigate the importance of immune cells to the efficacy of MSLN-TTC. MSLN-TTC treatment induced upregulation of DNA sensing pathway transcripts (IL-6, CCL20, CXCL10, and stimulator of interferon genes (STING)-related genes) in vitro as determined by RNASeq analysis. The results, including phospho-STING activation, were confirmed on the protein level. Danger-associated molecular pattern molecules were upregulated in parallel, leading to dendritic cell (DC) activation in vitro. MSLN-TTC showed strong antitumor activity (T:C 0.38, p<0.05) as a single agent in human MSLN-expressing MC38 tumor-bearing immunocompetent mice. Combining MSLN-TTC with anti-PD-L1 further enhanced the efficacy (T:C 0.08, p<0.001) as evidenced by the increased number of tumor-free surviving animals. MSLN-TTC monotherapy caused migration of CD103+ cDC1 DCs and infiltration of CD8+ T cells into tumors, which was enhanced on combination with anti-PD-L1. Intriguingly, CD8+ T-cell depletion decreased antitumor efficacy. These in vitro and in vivo data on MSLN-TTC demonstrate that the MoA of TTCs involves activation of the immune system. The findings are of relevance for other targeted radiotherapies and may guide clinical combination strategies.
doi:10.1136/jitc-2021-002387 pmid:34615703 pmcid:PMC8496392 fatcat:gto4cate4vg27lpp7mcydq4gdq

Mesothelin-targeted thorium-227 conjugate (MSLN-TTC): Preclinical evaluation of a new targeted alpha therapy for mesothelin-positive cancers

Urs B Hagemann, Christine Ellingsen, Joachim Schuhmacher, Alexander Kristian, Anne Mobergslien, Véronique Cruciani, Katrine Wickstroem, Christoph A. Schatz, Christoph Kneip, Sven Golfier, Roger Smeets, Steinar R Uran (+7 others)
2019 Clinical Cancer Research  
Hennekes and immediate family members hold ownership interest (including patents) in Bayer AG. D. Mumberg holds ownership interest (including patents) in Bayer AG. K.  ... 
doi:10.1158/1078-0432.ccr-18-3476 pmid:31064781 fatcat:qcvnghotx5h6lh7eorducvi624

Eingegangene Bücher

2021 Historische Zeitschrift  
Dominik Trump, Römisches Recht im Karolingerreich. (Studien zur Überlieferungs-und Rezeptionsgeschichte der ‚Epitome Aegidii'.) Ostfildern, Thorbecke 2021. 340 S., € 43,-.  ...  Hans-Günter Henneke / Klaus Ritgen, Kommunalpolitik und Kommunalverwaltung in Deutschland. München, Beck 2021. 290 S., € 29,95. Ulrich Herbert, Wer waren die Nationalsozialisten?  ... 
doi:10.1515/hzhz-2021-0019 fatcat:pgzxa5d7crco7n7kv2e2pp2fxu

Cycle-specific female preferences for visual and non-visual cues in the horse (Equus caballus)

Dominik Burger, Charles Meuwly, Selina Thomas, Harald Sieme, Michael Oberthür, Claus Wedekind, Sabine Meinecke-Tillmann, Cheryl S. Rosenfeld
2018 PLoS ONE  
determined by registering body height (distance from the ground to the withers in cm), weight (kg), body condition score (1 = emaciated to 5 = obese) (modified from Carroll and Huntington [54] and Henneke  ... 
doi:10.1371/journal.pone.0191845 pmid:29466358 pmcid:PMC5842875 fatcat:ecmyy3cdyvec5l5r2adqerfvbe

Effects of breed, management and personality on cortisol reactivity in sport horses

Fay J Sauer, Marco Hermann, Alessandra Ramseyer, Dominik Burger, Stefanie Riemer, Vinzenz Gerber
2019 PLoS ONE  
The body condition score (BCS) was recorded, according to the 9-point Henneke BCS system ranging from 1 (poor) to 9 (extremely fat) [42] .  ... 
doi:10.1371/journal.pone.0221794 pmid:31790402 pmcid:PMC6886778 fatcat:x3eeqf4qlzezxdlasn2cx533ku

Effects of breed, management and personality on cortisol reactivity in sport horses [article]

Fay J Sauer, Marco Hermann, Alessandra Ramseyer, Dominik Burger, Stefanie Riemer, Vinzenz Gerber
2019 bioRxiv   pre-print
The body 126 condition score (BCS) was recorded, according to the 9-point Henneke BCS system 127 ranging from 1 (poor) to 9 (extremely fat) [38].  ... 
doi:10.1101/739847 fatcat:kzwoqbaybjbqta6g7wp6gtzhia

Enterococcus faecalis Glycolipids Modulate Lipoprotein-Content of the Bacterial Cell Membrane and Host Immune Response

Christian Theilacker, Ann-Kristin Diederich, Andreas Otto, Irina G. Sava, Dominique Wobser, Yinyin Bao, Katrin Hese, Melanie Broszat, Philipp Henneke, Dörte Becher, Johannes Huebner, Lynn E. Hancock
2015 PLoS ONE  
Acknowledgments We are grateful to Ioana Toma, Türkan Sankic, and Dominik Anders for expert technical assistance. We would also like to thank Otto Holst for helpful discussions.  ... 
doi:10.1371/journal.pone.0132949 pmid:26172831 pmcid:PMC4501811 fatcat:egpbkq5zejhwvfirroskro7avy

03_Sozialmodell und Menschenbild in der "Hartz-IV"-Gesetzgebung

Ulrich Becker, Göttingen Academy Of Sciences
Aufl. 2004, S. 343 f. 47 Zu den Voraussetzungen nur Hans Günter Henneke, in: Hans-Joachim Knack (Hrsg.), VwVfG, 8.  ...  Vgl. auch Stefan Sell, Vom Vermittlungsskandal der Bundesanstalt für Arbeit zu Hartz IV, in: Dominik Haubner/Erika Mezger/Hermann Schwengel (Hrsg.), Agendasetting und Reformpolitik, 2005, S. 285 ff. 74  ... 
doi:10.26015/adwdocs-729 fatcat:6bib2s6cxngddovosk6ogns4qi

Differential Effects of Obesity, Hyperlipidaemia, Dietary Intake and Physical Inactivity on Type I Versus Type IV Allergies

Nathalie Rohmann, Liasita Munthe, Kristina Schlicht, Corinna Geisler, Tobias J. Demetrowitsch, Corinna Bang, Julia Jensen-Kroll, Kathrin Türk, Petra Bacher, Andre Franke, Karin Schwarz, Dominik M. Schulte (+1 others)
2022 Nutrients  
Procedures of sample collection and processing have recently been described in detail by Henneke et al. [11] .  ... 
doi:10.3390/nu14112351 pmid:35684151 pmcid:PMC9182605 fatcat:jgec7r47wba3tce7hjsewiussi

Einführung [chapter]

Nikolas Eisentraut
2020 Verwaltungsrecht in der Klausur  
Aufl. 2017 , § 11 Rn. 44.  S. nur Peuker, in: Knack/Henneke,VwVfG, 10.  ...  Aufl. 2018, § 41 Rn. 133; Ruffert, in: Knack/ Henneke, VwVfG, 10. Aufl. 2014, § 41 Rn. 41 .  ... 
doi:10.1515/9783110656220-011 fatcat:t7gs4f7bmffb3jgx7d5ofmrsmq

Transnationale Verwaltungsakte

Christoph Danninger
2019 unpublished
Henneke in Busch/Clausen/Dürr/Henneke/Meyer (Hg), Verwaltungsverfahrensgesetz (2000) § 35 VwVfG Rz 107; vgl auch die von Potacs vorgenommene Abgrenzung bzw Differenzierung zwischen einem "mehrstufigen  ...  Dominik Rabe, Der "Verwaltungsakt" nach deutschem und spanischem Recht (2011) 132f.  ... 
doi:10.25365/thesis.58397 fatcat:f6b3isxqzjgqnhr5ddxbtomlpe

Verwaltungsrecht in der Klausur

(:Unkn) Unknown, Universitätsbibliothek Der FU Berlin, Universitätsbibliothek Der FU Berlin, Nikolas Eisentraut
) ; Schoch, NVwZ 1985, 880 (885) .  Peuker, in: Knack/Henneke, VwVfG, 10.  ...  Aufl. 2018, § 41 Rn. 133; Ruffert, in: Knack/ Henneke, VwVfG, 10. Aufl. 2014, § 41 Rn. 41 .  ... 
doi:10.17169/refubium-26510 fatcat:ebt5xemidfandcvfg7d27jwlfi
« Previous Showing results 1 — 15 out of 21 results